Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Capsule without food Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Optimizing PTCy Dose and Timing

NCT03983850
View directory record Official record
Conditions
Graft Versus Host Disease, Hematologic Neoplasms
Interventions
Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524
View directory record Official record
Conditions
Essential Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Not applicable Interventional

A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia

NCT00538070
View directory record Official record
Conditions
Schizophrenia
Interventions
Sarcosine
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Not applicable Interventional Results available

Cytosponge and Dietary Therapy in EoE

NCT02599558
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Results available

Study of Oral Treatments for Hepatitis C

NCT02786537
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Harvoni Treatment Porphyria Cutanea Tarda

NCT03118674
View directory record Official record
Conditions
Porphyria Cutanea Tarda, Hepatitis C
Interventions
Harvoni
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
San Francisco, California • Winston-Salem, North Carolina • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HPG1860, Placebo
Drug
Lead sponsor
Hepagene (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 26, 2026, 12:24 PM EDT
Terminated Phase 3 Interventional

Chemoprevention of Colorectal Adenomas

NCT00486512
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy
Drug · Procedure
Lead sponsor
Colotech A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of a Delivery System on the Efficacy of a Probiotic Intervention

NCT01399996
View directory record Official record
Conditions
Delayed Transit Time, Irregular Bowel Function
Interventions
Yogurt smoothie without probiotic, Yogurt smoothie with probiotic added post fermentation, Yogurt smoothie with probiotic added pre-fermentation, A capsule containing the probiotic
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

NCT00661960
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
raltegravir, efavirenz
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

NCT00537420
View directory record Official record
Conditions
Obesity
Interventions
Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

NCT06665126
View directory record Official record
Conditions
Bacterial Vaginosis, Yeast Infection
Interventions
Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
Dietary Supplement
Lead sponsor
Happy V
Industry
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 12:24 PM EDT
Recruiting Phase 2 Interventional

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

NCT05405387
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Budesonide EC, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 26, 2026, 12:24 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sutetinib Maleate Capsule
Drug
Lead sponsor
Teligene US
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Glendale, California • La Jolla, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 26, 2026, 12:24 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342
View directory record Official record
Conditions
Solid Tumor
Interventions
TL118 Capsule
Drug
Lead sponsor
Teligene US
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Glendale, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

NCT00445146
View directory record Official record
Conditions
HIV Infections
Interventions
EVG, RTV, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
47
States / cities
Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

NCT00870363
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 26, 2026, 12:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

NCT04844424
View directory record Official record
Conditions
Healthy
Interventions
Milvexian
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT02560753
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 26, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

NCT02807051
View directory record Official record
Conditions
Drug Interaction Study
Interventions
Pacritinib, Clarithromycin, Pacritinib and Clarithromycin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 26, 2026, 12:24 PM EDT